



ANNUAL RESULTS 2010

STAR CONFERENCE March 23rd, 2011

Medical Laser Systems





- 2 EL.EN. GROUP
- 3 2010 RESULTS
- 4 2011 GUIDANCE








LASER

Light Amplification Stimulated by Emission of Radiation










The Laser Market



Laser sources

ONLY

Materials Processing

\$ 2,2 B


Medical and Aesthetic

\$ 0,45 B



Source: Laser focus World

El.En.: Trademarks and Markets




The MEDICAL Laser Market

THERAPEUTIC

2008 2009

\$2,3B \$1,9B


SUMMARY FIGURE GLOBAL MARKET FOR MEDICAL LASERS BY END USE, 2008-2014 (\$ MILLIONS)



Surgical, Aesthetic, Ophthalmic, Therapeutic, Service and Accessories



The AESTHETIC Laser Market



Lumenis (Aesth)
Cynosure (CYNO)
Cutera (CUTR)
Palomar (PMTI)
Syneron (ELOS)
Solta Medical (SLTM)
El.En. (aesth w/o Cyno)

2008 \$ 860M

\$618M

2009

-28%

2010

\$683M

+10%




The AESTHETIC Laser Market Shares

Revenues	in \$ M

	2008	2009	2010
El.En. Aesth	\$ 97,4	\$ 72,8	\$ 89,9
Cynosure	\$ 139,0	\$ 72,5	\$ 81,5
Peer group Total	860,7	617,7	683,7
% El.En.	11,3%	11,8%	13,1%
% Cyno	16,2%	11,7%	11,9%
% El.En. Group	27,5%	23,5%	25,1%



The INDUSTRIAL Laser Market



Laser sources market

El. En. Group

Source: Laser focus World

Laser Systems manufacturers,		Rev in \$ M		
	2008	2009	2010	
Rofin Sinar	575	349	423	
IPG	229	185	299	
Coherent	599	435	605	
Prima Industrie	367	300	325	
Trumpf AG	1.662	1.340	1.672 (*)	(*) Estimated
TOTAL	3.432	2.609	3.324	
% YoY Change		-24,0%	27,4%	
El.En. (Industrial)	32	22	34	€.6

Strategic strengths

- Multidisciplinary and multifacility R&D activity: sources, systems, applications.
- Covering both Medical and Industrial laser markets

INDUSTRIAL:

 Combine High tech laser source development with flexible production facilities in high growth areas

MEDICAL:

- Maximize market penetration by multi brand approach
- Open new markets by developing new applications
- Leverage worldwide distribution





2 EL.EN. GROUP






Group overview


High -Tech industrial group

- Develops, manufactures and distributes laser sources and laser systems for medical and industrial applications
- Know-how based on stratification of 30 years of multidisciplinary experience
- 2010 Consolidate Revenue 190 mln of euros, up 27% from 2009
- 969 employees
- Global positioning



Yearly consolidated revenues and Ebit







R&D activity

Clinical trials and validations of new therapeutic laser treatments and research on new applications of laser- tissue interaction for aesthetic medicine

Laser systems for regenerative medicine

Laser and ultrasound combination systems for minimally invasive surgery

Development of new cutting edge CO₂ platform

High power surgical lasers

Integrated laser systems for skin ulcers treatment

Home use systems: Unilever project

Further improvements in laser lipolysis and cellulite treatment systems

Cutting and welding applications for 5 axes laser systems




R&D expenses as of December 31st, 2010

	31/12/09	31/12/10	Var.%
R&D expenses	11.381	12.333	8,4%
Percentage on group revenues	8%	6%	
Grants	1.138	1.018	-10,5%





Innovation: Smartxide²



• CO₂ Laser

- CO₂ Laser
- Radiofrequency





Courtesy of Campus Biomedico University of Rome and University of Florence and SILD



Medical/Aesthetic

Aesthetic:



Hair Removal

Vascular Lesions

Skin Rejuvenation

Pigmented Lesions

Treatment of Cellulite

Acne

Tattoo Removal

Anti - Aging

LaserBody Sculpting

Removal of Unwanted Fat















ENT

Gynaechology

Urology

Endovascular

Onchology

Dermatology

Psoriasis and Vitiligo

Dentistry

Therapy



Cynosure



2002 Acquisition of 70% share price \$3,5

2003-2004 Turnaround

2005 Nasdaq IPO share price \$ 15

holding down to 35%

2007 Stock sale share price \$ 29

holding down to 23%

Control and consolidation allowed by a statutory clause



Cynosure

Strategic cooperation:

R&D: Smartlipo MPX – Triplex - Cellulaze

Distribution: Smartlipo - Fractional CO₂ - Tattoo


Sales of ex Cyno El.En. group to Cynosure

(Euro 000), and % on ex Cyno Aesthetic sales

2008	2009	2010
12.560	4.369	4.163
16,8%	7,8%	6,0%



Cynosure





Medical Laser Snapshot Europe Far East USA 2009/

Industrial Laser Snapshot Europe/ Far East America



3 2010 RESULTS





Consolidated financial results as of December 31st, 2010

Title O.	31/12/09	Inc.%	31/12/10	Inc.%	Var.%
			unaudited		
Revenues	149.111	100,0%	189.797	100,0%	27,3%
Gross margin	79.287	53,2%	100.448	52,9%	26,7%
EBITDA	(4.026)	-2,7%	14.297	7,5%	
EBIT	(12.598)	-8,4%	5.422	2,9%	
Income before taxes	(12.331)	-8,3%	4.689	2,5%	
Net Income (Loss)	(5.258)	-3,5%	1.268	0,7%	
	31/12/09		31/12/10		
Net financial position	68.891		74.900		




Consolidated financial results as of December 31st, 2010 (w/o Cynosure)

Think of	31/12/09	Inc.%	31/12/10	Inc.%	Var.%
			unaudited		
Revenues	101.764	100,0%	132.566	100,0%	30,3%
Gross margin	50.325	49,5%	67.076	50,6%	33,3%
EBITDA	2.282	2,2%	13.327	10,1%	484,1%
EBIT	(1.454)	-1,4%	8.361	6,3%	
Income before taxes	(2.016)	-2,0%	7.697	5,8%	
Net Income (Loss)	(3.071)	-3,0%	2.200	1,7%	
	31/12/09		31/12/10		
Net financial position	8.830		10.042		



El.En. –

Revenues breakdown by business



El.En. –

Medical and aesthetic sector

El.En.


Laser sources

Cynosure

Medical


Aesthetic Surgical CO₂ Physiotherapy Dental







El.En. – Industrial sector



Tax Rate

4.255

Tax Rate	Pretax	Income
		taxes

4.689

Actual tax rate (with Cynosure)

91%

Actual tax rate (w/o Cynosure) 49% 7.697 3.745

Undeductible devaluation in equity investments 27,5% (716)

Pretax loss w/o deferred income tax accruals 27,5% (396)

One time tax charge (302)

Theoretical tax rate 30% 7.697 2.332





4 2011 GUIDANCE





2010 - Out of the downturn

Rapidly

Industrial laser systems in China and Brazil
Surgical laser systems by Quanta System
Aesthetic laser systems in Europe and Far East

Slowly

Aesthetic laser systems in US and Spain

...and investing

Distribution in the US for Deka Dental and Medical Distribution in Italy for the SPA market



2011 forecast - El.En. stand alone

 2010
 2011
 Var.


 Sales
 133 Mln
 146 Mln
 10%

 EBIT %
 6,3%

For 2011, we expect an improvement in profitability



El.En. and Cynosure stock









El.En. SPA

Enrico ROMAGNOLI

Investor Relator

tel. +39 055-8826807

E-mail: finance@elen.it

POLYTEMS HIR SRL

Bianca FERSINI MASTELLONI

Financial Communication & Press office
Tel. +39 06-6797849 / +39 06-69923324

E-mail: b.fersini@polytemshir.it

